title: The role of carbonic anhydrase IX in hypoxia control in OSCC.
abstract: Tumoral microenvironments play a key role in the evolution of solid tumors. Tumor hypoxia is actively involved in the promotion of genetic instability, the invasive capacity of tumor cells, metastasis, and a worsening of the clinical evolution. Endogenous hypoxia markers are controlled by hypoxia-related genes, formed by HIF-1, which is related to several target genes that involve the energy metabolism, angiogenesis, and transmembrane carbonic anhydrases (CAs), mainly CA-IX that is one of the tumor-related carbonic anhydrases. The goal of this paper is to establish the role of CA-IX as a hypoxia marker in OSCC, while analyzing its expression in this type of tumors and its relationship with several clinical and pathological parameters and prognosis, evaluating its relationship with angiogenesis, other hypoxia markers, and clarifying its role in chemotherapy and radiotherapy resistance.
authors.affiliation: Oral Medicine, Oral Surgery and Implantology Unit, Faculty of Medicine and Dentistry, Instituto de Investigación Sanitaria de Santiago (IDIS), Santiago de Compostela, Spain. perezsayans@gmail.com
authors.forename: Mario
authors.initials: M
authors.lastname: Pérez-Sayáns
authors.forename: Claudiu T
authors.initials: CT
authors.lastname: Supuran
authors.forename: Silvia
authors.initials: S
authors.lastname: Pastorekova
authors.forename: José Manuel
authors.initials: JM
authors.lastname: Suárez-Peñaranda
authors.forename: Gayoso-Diz
authors.initials: GD
authors.lastname: Pilar
authors.forename: Francisco
authors.initials: F
authors.lastname: Barros-Angueira
authors.forename: José Manuel
authors.initials: JM
authors.lastname: Gándara-Rey
authors.forename: Abel
authors.initials: A
authors.lastname: García-García
mesh_terms: D000951:Antigens, Neoplasm / Q000096:biosynthesis / Q000235:genetics / Q000502:physiology*; D000970:Antineoplastic Agents; D000071231:Carbonic Anhydrase IX; D002256:Carbonic Anhydrases / Q000096:biosynthesis / Q000235:genetics / Q000502:physiology*; D002294:Carcinoma, Squamous Cell / Q000201:enzymology*; D019008:Drug Resistance, Neoplasm; D004921:Erythropoietin / Q000502:physiology; D015971:Gene Expression Regulation, Enzymologic; D015972:Gene Expression Regulation, Neoplastic; D051272:Glucose Transporter Type 1 / Q000096:biosynthesis / Q000502:physiology; D006258:Head and Neck Neoplasms / Q000201:enzymology; D006801:Humans; D000860:Hypoxia / Q000201:enzymology*; D051795:Hypoxia-Inducible Factor 1, alpha Subunit / Q000096:biosynthesis / Q000502:physiology; D019394:Ki-67 Antigen / Q000096:biosynthesis / Q000502:physiology; D009062:Mouth Neoplasms / Q000201:enzymology*; D009389:Neovascularization, Pathologic; D011836:Radiation Tolerance; D017467:Receptors, Erythropoietin / Q000502:physiology
chemical_list: D000951:Antigens, Neoplasm; D000970:Antineoplastic Agents; D051272:Glucose Transporter Type 1; C497442:HIF1A protein, human; D051795:Hypoxia-Inducible Factor 1, alpha Subunit; D019394:Ki-67 Antigen; D017467:Receptors, Erythropoietin; D004921:Erythropoietin; C089226:CA9 protein, human; D000071231:Carbonic Anhydrase IX; D002256:Carbonic Anhydrases